Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR3 | P46089 | 5/20 | 0.42 |
| ▸ | PIM1 | P11309 | 1/20 | 0.40 |
| ▸ | NPC1 | O15118 | 2/20 | 0.38 |
| ▸ | RAB9A | P51151 | 2/20 | 0.38 |
| ▸ | GAA | P10253 | 2/20 | 0.38 |
| ▸ | GMNN | O75496 | 1/20 | 0.38 |
| ▸ | USP2 | O75604 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | TP53 | P04637 | 1/20 | 0.38 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.38 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.38 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.38 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.38 |
| ▸ | PKM | P14618 | 1/20 | 0.38 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.38 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.38 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.38 |
| ▸ | SCN4A | P35499 | 1/20 | 0.38 |
| ▸ | BLM | P54132 | 1/20 | 0.38 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5541794 | 0.95 | GPR3 (0.41) | GPR3PIM1NPC1RAB9AGAA | |
| SCHEMBL7595319 | 0.81 | ABL1 (0.37) | CYP1A2KIF11 | |
| SCHEMBL208820 | 0.75 | CYP1A2 (0.30) | CYP1A2 | |
| SCHEMBL314646 | 0.75 | CYP2A6 (0.54) | NPC1RAB9ACYP1A2CYP3A4CYP2C9 | |
| SCHEMBL17816158 | 0.74 | CYP1A2 (0.52) | GPR3PIM1NPC1RAB9AGAA | |
| SCHEMBL2723529 | 0.74 | CYP1A2 (0.52) | GPR3PIM1NPC1RAB9AGAA | |
| SCHEMBL28109965 | 0.73 | GPR3 (0.42) | GPR3TP53CYP3A4ALOX15BLM | |
| SCHEMBL1370905 | 0.73 | BACE1 (0.42) | PIM1SCN4AMAPK1KDM4EKMT2A | |
| SCHEMBL3224574 | 0.73 | NPC1 (0.41) | GPR3NPC1RAB9AGAAGMNN | |
| SCHEMBL16289492 | 0.73 | NPC1 (0.44) | GPR3PIM1NPC1RAB9AGAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2010019828-A1 | GLUCAGON RECEPTOR ANTAGONISTS | METABASIS THERAPEUTICS, INC. (US) | 2010-02-18 | — | — | WO | claimed |
| EP-3178323-B1 | NOXIOUS ARTHROPOD CONTROL AGENT CONTAINING AMIDE COMPOUND | SUMITOMO CHEMICAL CO (JP) | 2021-06-23 | — | — | EP | disclosed |
| US-9854803-B2 | Noxious arthropod control agent containing amide compound | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2018-01-02 | — | — | US | disclosed |
| US-20170215424-A1 | NOXIOUS ARTHROPOD CONTROL AGENT CONTAINING AMIDE COMPOUND | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2017-08-03 | — | — | US | disclosed |
| EP-3178323-A1 | NOXIOUS ARTHROPOD CONTROL AGENT CONTAINING AMIDE COMPOUND | Sumitomo Chemical Company, Limited (JP) | 2017-06-14 | — | — | EP | disclosed |
| CN-106572659-A | Noxious arthropod control agent containing amide compound | 住友化学株式会社 | 2017-04-19 | — | — | CN | disclosed |
| CN-104955332-B | The method of preventing and treating arthropod insect | 住友化学株式会社 | 2017-03-29 | — | — | CN | disclosed |
| CN-102532162-B | 2,3-dihydro-6-nitroimidazo[2,1-b]oxazoles | OTSUKA PHARMA CO LTD | 2015-05-27 | — | — | CN | disclosed |
| EP-2570418-A2 | 2,3-dihydro-6-nitroimidazo[2,1-b]oxazoles compound | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2013-03-20 | — | — | EP | disclosed |
| EP-1555267-B1 | 2,3-DIHYDRO-6-NITROIMIDAZO[2,1-b]OXAZOLES | OTSUKA PHARMA CO LTD (JP) | 2013-01-16 | — | — | EP | disclosed |
| WO-2010019828-A1 | GLUCAGON RECEPTOR ANTAGONISTS | METABASIS THERAPEUTICS, INC. (US) | 2010-02-18 | — | — | WO | disclosed |
| CN-101255170-A | 2,3-dihydroimidazo[2,1-b]oxazole compound | OTSUKA PHARMA CO LTD (JP) | 2008-09-03 | — | — | CN | disclosed |
| CN-101172981-A | 2,3-dihydroimidazo[2,1-b]oxazole compound | OTSUKA PHARMA CO LTD (JP) | 2008-05-07 | — | — | CN | disclosed |
| CN-100366624-C | 2, 3-dihydro-6-nitroimidazo [2,1-b ] * azole compounds | OTSUKA PHARMA CO LTD (JP) | 2008-02-06 | — | — | CN | disclosed |
| US-7262212-B2 | 2,3-dihydro-6-nitroimidazo[2,1-b]oxazoles | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2007-08-28 | — | — | US | disclosed |
| CN-1964947-A | Pyrazole derivatives, compositions containing the same and methods of use thereof | MERCK & CO INC (US) | 2007-05-16 | — | — | CN | disclosed |
| US-20060094767-A1 | 2,3-Dihydro-6-nitroimidazo[2,1-b]oxazoles | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2006-05-04 | — | — | US | disclosed |
| CN-1705670-A | 2, 3-dihydro-6-nitroimidazo [2, 1-b ] oxazole compounds | OTSUKA PHARMA CO LTD (JP) | 2005-12-07 | — | — | CN | disclosed |
| EP-1555267-A1 | 2,3-DIHYDRO-6-NITROIMIDAZO 2,1-b OXAZOLES | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2005-07-20 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060094767-A1 | 2,3-Dihydro-6-nitroimidazo[2,1-b]oxazoles | NR2C2, NR4A3, NR4A2 | GPR3 80/4885PIM1 3129/4885NPC1 2404/4885 |
| US-20170215424-A1 | NOXIOUS ARTHROPOD CONTROL AGENT CONTAINING AMIDE COMPOUND | TRPA1, OPRM1, OPRL1 | GPR3 1487/4885PIM1 4491/4885NPC1 3719/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.